News

08 Nov 2017

REPROCELL Chooses Science Exchange as the Preferred Partner to Increase Accessibility of its Predictive Drug Discovery Services

Press release: REPROCELL Chooses Science Exchange as the Preferred Partner to Increase Accessibility of its Predictive Drug Discovery Services
Read More >>

08 Nov 2017

Visit REPROCELL at the “North East England Life Science Showcase” in Cambridge, MA (USA) on November 30, 2017

Visit REPROCELL at the “North East England Life Science Showcase” in Cambridge, MA (USA) on November 30, 2017
Read More >>

07 Nov 2017

Prof Stefan Przyborski to chair and speak at SMi Group’s 3D Cell Culture 2018 Conference

REPROCELL Europe Ltd's CSO Prof Stefan Przyborski to chair and speak at SMi Group’s 3D Cell Culture 2018 Conference
Read More >>

27 Sep 2017

Article by Dr David Bunton (co-authored) in the European Pharmaceutical Review, Autumn 2017

REPROCELL Europe Ltd’s CEO, Dr David Bunton, has co-authored an article titled New Strategy that has been published in the European Pharmaceutical Review, Autumn 2017. The article is in the EPR’s section, Applied Research, Development and Production. It is co-authored by David Bunton at REPROCELL Europe, Marian McNeil at Stratified Medicine Scotland and Pamela Brankin at Aridhia.
Read More >>

1 2 3 4 >>

Proteon and Biopta publication shows promising nonclinical results on Proteon's Vonapanitase

21/04/2016

Proteon Therapeutics Announces Publication in the Journal of Cardiovascular Pharmacology of Promising Nonclinical Results for Vonapanitase in Peripheral Artery Disease

Proteon Therapeutics Inc. (Nasdaq:PRTO), a longstanding client of Biopta, is developing novel, first-in-class pharmaceuticals to address the medical needs of patients with kidney and vascular diseases. Proteon today announced publication of additional nonclinical data on investigational drug vonapanitase in peripheral artery disease (PAD). The ex vivo study demonstrated that a single treatment of vonapanitase following angioplasty of excised atherosclerotic human tibial arteries altered artery compliance. Increased compliance is known to correlate with arterial dilation.

The study, titled Recombinant Human Elastase Alters the Compliance of Atherosclerotic Tibial Arteries After Ex Vivo Angioplasty, was published in the Journal of Cardiovascular Pharmacology. Proteons Senior Vice President and Chief Medical Officer, Steven Burke, M.D., is the senior author of the published manuscript. Dr Karen Bingham and Dr Emma Moss of Biopta were co-authors. Proteon's press release can be read here

Live chat by BoldChat